EYE SHUNT WITH POROUS STRUCTURE

• US 20120310137A1
• Filed: 06/01/2012
• Published: 12/06/2012
• Est. Priority Date: 06/02/2011
• Status: Abandoned Application

• Current Assignee: Thomas A. Silvestrini
• Original Assignee: Thomas A. Silvestrini
• Inventors: SILVESTRINI, Thomas A.
• Application Number:
  US13/487,007
• Publication Number:
  US 20120310137A1
• Time in Patent Office: Days
• US Class Current: 604/8
• CPC Class Codes: A61F 2250/0024 made from both porous and non-porous parts, e.g. adjacent parts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002

Abstract

Disclosed are devices and methods for treatment of eye disease such as glaucoma. An implant is placed in the eye wherein the implant provides a fluid pathway for the flow or drainage of aqueous humor from the anterior chamber to the supraciliary or the suprachoroidal space, or to any space in the eye where drainage to that location will lower the intraocular pressure. The implant may include an elongate compressible structure and may be implanted in the eye using a delivery system that folds and or compresses the implant to provide a smaller cross-sectional area to allow a more minimally-invasive procedure. The compressibility of the implant is provided by a porous structure that may be collapsed by compression and delivered through a tube-shaped introducer.

Claims

1. An ocular implant, comprising

an elongate member having a flow pathway,

at least one inflow area communicating with the flow pathway, and

an outflow area communicating with the flow pathway,

wherein the elongate member includes at least one porous structure and is configured to transition between a compressed shape when compressed and an expanded shape when uncompressed;

wherein the elongate member is configured to be positioned in an eye such that the inflow area communicates with an anterior chamber of the eye and the outflow area communicates with a region of the eye that will increase aqueous outflow to help maintain a proper pressure of the eye.

2. An implant as in claim 1, wherein the elongate member is configured to transition from the compressed shape to the expanded shape without a substantial change in a length of the elongate member.

3. An implant as in claim 1, wherein at least one porous structure is permeable to a flow of aqueous and other body fluids.

4. An implant as in claim 1, wherein at least part of an outer surface of the elongate member includes pores having a pore size and pore size distribution that prevents excessive fibrosis and scarring of the elongate member.

5. An implant as in claim 4, wherein substantially all the pores have a similar size, wherein a mean size of the pores is between about 20 and about 60 micrometers, wherein substantially all the pores are each connected to adjacent pores, and wherein the pores allow permeable flow of fluids between the pores.

6. An implant as in claim 1, wherein at least part of an outer surface of the elongate member has a pore size and pore size distribution that allows fibrous in growth into the elongate member.

7. An implant as in claim 1, wherein at least part of an outer surface of the elongate member has a surface that helps prevent migration of the elongate member in tissue.

8. An implant in claim 1, wherein the elongate member is in a state of reduced diameter under compression and transitions to a state of enlarged diameter upon removal of compression.

9. An implant in claim 2, wherein the elongate member is in a state of reduced diameter under compression and transitions to a state of enlarged diameter upon removal of compression.

57. An implant as in claim 1, wherein the region of the eye is a supraciliary space and/or a suprachoroidal space of the eye.

58. An implant as in claim 1, wherein the elongate member further comprises at least one non-porous structure.

10-25. -25. (canceled)

26. A method of implanting an ocular device into an eye, comprising:

forming an incision in a cornea of the eye;

compressing an implant;

inserting the implant through the incision into an anterior chamber of the eye;

passing the implant along a pathway from the anterior chamber into a supraciliary space and/or a suprachoroidal space of the eye;

positioning the implant in a first position such that a proximal portion of the implant communicates with the anterior chamber and a distal portion of the implant communicates with the supraciliary space and/or the suprachoroidal space to provide a path between the supraciliary space and/or the suprachoroidal space and the anterior chamber; and

permitting the implant to expand to an expanded shape, wherein the implant defines a fluid passageway in the expanded shape that allows fluid to communicate between the anterior chamber and the supraciliary space and/or the suprachoroidal space.

27. A method as in claim 26, wherein the implant is at least partially formed of a porous structure.

28. A method as in claim 26, wherein the implant includes a first portion formed at least partially of a porous structure and a second portion formed at least partially of a non-porous structure.

29. A method as in claim 26, further comprising inserting the implant into a delivery tube of a delivery device such that the delivery tube exerts a compressive force on the implant.

30. A method as in claim 26, comprising releasing the implant from compression after positioning the implant in the first position.

31. A method as in claim 26, wherein the fluid passageway comprises a lumen that extends through the implant.

32. A method as in claim 26, wherein the fluid passageway comprises a permeable porous channel that extends through the implant.

34. A method as in claim 26, wherein a distal end of the implant is compressed, and further comprising creating a dissection in a tissue boundary between a ciliary body and a sclera of the eye using the distal end of the implant.

35. A method as in claim 26, wherein passing the implant along a pathway from the anterior chamber into the supraciliary space comprises contacting a scleral spur of the eye and sliding the implant into the supraciliary space the just below the scleral spur.

33. (canceled)

36-56. -56. (canceled)